PDS Biotechnology Corpora... (PDSB)
| Bid | 1.51 |
| Market Cap | 70.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.5M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.65 |
| Forward PE | -1.87 |
| Analyst | Buy |
| Ask | 1.53 |
| Volume | 306,744 |
| Avg. Volume (20D) | 492,191 |
| Open | 1.59 |
| Previous Close | 1.62 |
| Day's Range | 1.54 - 1.61 |
| 52-Week Range | 0.85 - 4.42 |
| Beta | 1.24 |
About PDSB
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for PDSB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · proactiveinvestors.co.uk
EMV Capital portfolio company PDS Biotech advances cancer trialPDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head ...
1 month ago · seekingalpha.com
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Offic...
2 months ago · seekingalpha.com
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief M...